At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
Sintilimab Combined With Docetaxeldrug
Likely dose
Sintilimab Combined With Docetaxel 75mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Single Center, Single Arm Phase II Study on Efficacy Evaluation and Bio-marker Analysis of Sintilimab Combined With Docetaxel for Double Platinum-based Chemotherapy Failure Advanced Non-small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating Sintilimab Combined With Docetaxel for Non-small Cell Lung Cancer. Completed, enrolled 30 participants across 1 site.
Detailed Summary
The study aim to Evaluate the combination of ididilimumab and docetaxel alone in the treatment of previous platinum-containing double-drug chemotherapy according to RECIST 1.1Objective remission rate of advanced or metastatic non-small cell lung cancer with negative, driving gene negative (EGFR, ALK, ROS1); (ORR).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartJan 2019
First PostedJan 2019
Primary CompletionDec 2021
Study CompletionMar 2022
TodayJul 2026
First PostedJan 10, 2019
Enrollment StartJan 1, 2019
Primary CompletionDec 30, 2021
Study CompletionMar 1, 2022
TodayJul 1, 2026
Enrollment to primary: 3.0 yearsPosted 7.5 years ago
Interventions
Sintilimab Combined With Docetaxeldrug
Sintilimab 200mgi.v q3w Docetaxel 75mg/m2 i.v q3w